27 Drydock Ave
55 articles about Emulate, Inc.
EMulate Therapeutics Inc. Announces Publication of Clinical Results at the SNO 2023 Conference: GBM and DIPG
EMulate Therapeutics, Inc. (EMTx) proudly announced today the acceptance of their abstract for presentation and publication in the 28th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 2023, in Vancouver, British Columbia.
Emulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics Markets
Emulate, Inc., the leading provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.
Emulate, Inc., a leading provider of next-generation in vitro models, announced that it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2023.
Emulate Publishes Landmark Study Validating Organ-on-a-Chip Technology for Predictive Toxicology in Preclinical Development
Emulate, Inc. today announced the publication of a landmark study, “Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology,” in Nature Communications Medicine demonstrating that the Emulate human Liver-Chip could improve patient safety and reduce small-molecule clinical trial failures due to liver toxicity by up to 87%.
EMulate Therapeutics today announced the formation of a new technology advisory committee that will bring expertise across multiple disciplines to facilitate company growth and innovation.
Emulate Announces New Gene Therapy Application Enabling Accelerated Development of Treatments for Genetic Diseases with Organ-on-a-Chip Technology
Emulate, Inc. , a leading provider of next-generation in vitro models, today announced the launch of its new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks, not months, as with animal models.
The model has been validated against clinically relevant IBD therapies to demonstrate efficacy and mechanism of action, enabling drug developers to gain more accurate therapeutic insights.
Emulate Announces Launch of Immune Cell Recruitment Application for the Colon Intestine-Chip to Aid in the Study of Inflammatory Bowel Disease
Emulate, Inc. today announced its new colon immune cell recruitment application, enabling the most human-relevant preclinical assessment of inflammatory bowel disease (IBD) drug candidates.
Emulate, Inc., a leading provider of next-generation in vitro models, today announced the promotion of Lorna Ewart, PhD, to Chief Scientific Officer.
Emulate Brain-Chip to Study the Effects of Microgravity on Human Brain Physiology at the International Space Station
Emulate, Inc., a leading provider of next-generation in vitro models, today announced that the Brain-Chip is being sent to the International Space Station U.S. National Laboratory (ISS National Lab) to study the effects of microgravity on human brain physiology as part of the Tissue-Chips in Space initiative sponsored by the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) and the International Space Station National Lab (ISS-NL).
EMulate Therapeutics Has Incorporated Two Wholly Owned Subsidiaries to Deploy Its Platform Technology for the Treatment of Pain Management and Numerous Mental Health Conditions.
Emulate Introduces the Second-Generation Zoë® Culture Module for Replicating Complex Human Biology and Drug Effect
Emulate Introduces the Second-Generation Zoë ® Culture Module for Replicating Complex Human Biology and Drug Effect
Emulate Inc., a leading provider of next-generation in vitro models, today announced the appointment of Scott D. Kantor as Chief Financial Officer.
EMulate Therapeutics to Participate in the Venture Summit/Virtual Connect West on March 17 at 12pm PST
EMulate Therapeutics Inc, a clinical-stage therapeutic device company, announced that management will participate in the Venture Summit...
Technology Visionary will Offer Strategic Insight to Guide Ongoing Research & Development of Market Leading Organ-on-a-Chip Technology
Expanded In Vitro Modeling Tools Will Enable Researchers to Better Understand the Effects of Advanced Biologics and Gene Therapies
Emulate, Inc., a leading provider of advanced in vitro models, today announced that its Alveolus Lung-Chip is being used by the U.S. Army to understand how the SARS-CoV-2 virus interacts with lung cells.
Emulate Signs Collaborative Agreement with the FDA to Apply Lung-Chip to Evaluate Safety of COVID-19 Vaccines and Protective Immunity Against SARS-CoV-2
Agency-wide CRADA agreement also includes studies with Brain-Chip in Alzheimer’s disease, Intestine-Chip in microbiome health, and Liver-Chip in individualized toxicity responses
Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman
Company Builds Leadership Team for Next Stage of Growth with Expanded Commercialization of Organs-on-Chips Product Suite
Emulate Achieves 150 User Installations of Zoë® Instrument as a Lab-Ready Organs-on-Chips Platform, Along With 3 Commercially Available Chips for Liver, Kidney, and Intestine
Platform adopted by 10 of the top 25 biopharmaceutical companies, by U.S. governmental agencies, and by academic research centers worldwide